腎細胞癌患者の治療に使用されるカボザンチニブに関する調査

基本情報

NCT ID

NCT04804813

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

388

治験依頼者名

Takeda

概要

This study is a survey in Japan of Cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with renal cell carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 26 weeks.

対象疾患

介入

依頼者（Sponsor）